investors

Press Releases
Date Title and Summary View
October 3, 2017 LOS ANGELES, Oct. 3, 2017 /PRNewswire/ -- ImmunoCellular Therapeutics, Ltd. ("ImmunoCellular") (NYSE MKT: IMUC), a biotechnology company developing immunotherapies for the treatment of cancer based on Stem-to-T-Cell research, announced today that Anthony Gringeri, Ph.D., President and Chief Executive Officer, Steven Swanson, Ph.D., Sr. VP, Research...
September 13, 2017 LOS ANGELES, Sept. 13, 2017 /PRNewswire/ -- ImmunoCellular Therapeutics, Ltd. ("ImmunoCellular" or the "Company") (NYSE MKT: IMUC) today announced that the NYSE MKT LLC (the "NYSE MKT") has accepted the Company's plan to regain compliance with the exchange's continued listing standards set forth in Sections 1003(a)(i), 1003(a)(ii) and 1003(a)(iii) ...
August 23, 2017 LOS ANGELES, Aug. 23, 2017 /PRNewswire/ -- ImmunoCellular Therapeutics, Ltd. ("ImmunoCellular") (NYSE MKT: IMUC) announced today that it plans to continue strategies to refocus and reallocate its available resources on its promising Stem-to-T-Cell research program. ImmunoCellular's Stem-to-T-Cell program is designed to provide a novel method of har...
August 14, 2017 LOS ANGELES, Aug. 14, 2017 /PRNewswire/ -- ImmunoCellular Therapeutics, Ltd. ("ImmunoCellular") (NYSE MKT: IMUC) today announced financial results for the second quarter 2017.   For the quarter ended June 30, 2017, ImmunoCellular incurred a net loss of $3.6 million, or $1.02 per basic and diluted s...
July 18, 2017 LOS ANGELES, July 18, 2017 /PRNewswire/ -- ImmunoCellular Therapeutics, Ltd. ("ImmunoCellular") (NYSE MKT: IMUC) today announced the pricing of an underwritten public offering of 5,000 shares of its Series B 8% Mandatorily Convertible Preferred Stock ("Preferred Stock") and related warrants ("Warrants") to purchase up to 9,000 shares of Preferred S...
June 29, 2017 LOS ANGELES, June 29, 2017 /PRNewswire/ -- ImmunoCellular Therapeutics, Ltd. ("ImmunoCellular") (NYSE MKT: IMUC) today announced it has received notification from the NYSE MKT LLC that the Company is not in compliance with certain NYSE MKT continued listing standards relating to stockholders' equity.   ...
June 21, 2017 LOS ANGELES, June 21, 2017 /PRNewswire/ --- ImmunoCellular Therapeutics, Ltd. ("ImmunoCellular") (NYSE MKT: IMUC) today provided an update on the strategic review of its financing and development strategies for ICT-107, its patient-specific, dendritic cell-based immunotherapy for patients with newly diagnosed glioblastoma. ...
June 12, 2017 LOS ANGELES, June 12, 2017 /PRNewswire/ -- ImmunoCellular Therapeutics, Ltd. ("ImmunoCellular") (NYSE MKT: IMUC) today announced that Anthony J. Gringeri, PhD, President and Chief Executive Officer of ImmunoCellular, will present a corporate overview and business update at the Marcum MicroCap Conference on Thursday, June 15, 2017 at 10:00 am ET at ...
June 5, 2017 LOS ANGELES, June 5, 2017 /PRNewswire/ -- ImmunoCellular Therapeutics, Ltd. ("ImmunoCellular") (NYSE MKT: IMUC) today announced the presentation of data from the phase 1 clinical trial of ICT-121 in patients with recurrent glioblastoma. The data from the 20-patient, open-label, multi-center study show that 6 of 20 patients are alive (as of April 20...
May 15, 2017 LOS ANGELES, May 15, 2017 /PRNewswire/ -- ImmunoCellular Therapeutics, Ltd. ("ImmunoCellular") (NYSE MKT: IMUC) today announced financial results for the first quarter 2017 and a re-evaluation of its financing and development strategies for ICT-107, its patient-specific, dendritic cell-based immunotherapy for patients with newly diagnosed glioblast...
1
... NextLast
Add to Briefcase = add release to Briefcase
Copyright 2017 by Immunocellular Therapeutics, Ltd.
All Rights Reserved